Bedford Group Transearch Life Sciences is proud to announce the release of its 6th annual publication; 2026 Executive and Board Compensation in the Biotechnology Industry.
This complimentary report serves as a vital benchmarking resource for biotechnology organizations developing compensation strategies to attract, engage, and retain top executive and board talent in a highly competitive market.
This year’s edition expands to include companies with market caps of up to US$5 billion, covering 718 Named Executive Officers and more than 1,250 Board Members at 199 Nasdaq-listed companies. It benchmarks pay by company size and tracks how CEO and CFO pay changed at the same companies from fiscal 2024 to 2025.
Among the key findings:
- Median base salary rose 4% year over year for both CEOs and CFOs
- CFO turnover rose for a second straight year, from 17.5% in fiscal 2023 to 21% in 2024 and 25% in 2025
- Female representation held at 29% among Board Members and rose from 11.7% to 15.6% among Board Chairs
The full report is available for complimentary download here.
About Bedford Group Transearch
Founded in 1979, Bedford Group Transearch is one of North America’s leading privately held executive search firms, recognized for its deep expertise in the Life Sciences. With offices across Canada and the United States, Bedford partners with organizations ranging from innovative startups to global multinationals. The firm’s Life Sciences practice spans Pharmaceuticals, Biotechnology, Clinical Research, Pharmacy, and MedTech, helping clients build world-class executive leadership teams equipped to drive growth and innovation.
Learn more at www.bedfordgroup.com/healthcare